Molecule
Spinosad is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older, among other approved uses. It is available as topical suspension. MedsAcross supplies Spinosad for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
NATROBA is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. NATROBA is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older.
Source: US FDA prescribing information
Spinosad causes neuronal excitation in insects. After periods of hyperexcitation, lice and mites become paralyzed and die.
Source: US FDA prescribing information
For topical use only. Not for oral, ophthalmic, or intravaginal use. Treatment of head lice infestations: Shake bottle well Apply a sufficient amount to cover dry scalp, then apply to dry hair Rinse off with warm water after 10 minutes Repeat treatment only if live lice are seen 7 days after first treatment Treatment of scabies infestations: Shake bottle well Apply product to skin by rubbing it in to completely cover the body from the neck down to the soles of the feet Patients with balding scalp should also apply product to the scalp, hairline, temples, and forehead Allow to absorb in the skin and dry for 10 minutes before getting dressed Leave on the skin for at least 6 hours before showering or bathing
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Benzyl Alcohol Toxicity: Not recommended in infants below the age of 6 months, potential for increased systemic absorption. Benzyl Alcohol Toxicity NATROBA contains benzyl alcohol and is not approved for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously.
Source: US FDA prescribing information
Most common adverse events for lice treatment (>1%) were application site erythema and ocular erythema. Most common adverse reactions for scabies treatment (>1%) were application site irritation (pain and burning) and dry skin.
Source: US FDA prescribing information
Store at 25° C (77° F), excursions permitted to 15° to 30° C (59° to 86° F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Spinosad, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Spinosad 9 mg/mL topical suspensionTopicalGeneric name | — | US FDA | Available on request |
| Natroba 9 mg/mL topical suspensionTopical | Cipher Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 18 January 2011 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Spinosad in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Spinosad and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Spinosad, including Natroba.
Yes. The US FDA first approved Spinosad on 18 January 2011, according to Drugs@FDA.
No listed presentation of Spinosad is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.